Anti-BCL9L antibody (ab113110)
Key features and details
- Rabbit polyclonal to BCL9L
- Suitable for: ICC, WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-BCL9L antibody
See all BCL9L primary antibodies -
Description
Rabbit polyclonal to BCL9L -
Host species
Rabbit -
Specificity
ab113110 is predicted to not cross-react with other BCL family members. At least four isoforms of BCL9L are known to exist; ab113110 will detect all four. -
Tested applications
Suitable for: ICC, WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide containing a 20 amino acid sequence from the N terminal region of Human BCL9L (NP_872363).
-
Positive control
- HeLa whole cell lysate (ab150035).
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at 4°C (stable for up to 12 months). -
Storage buffer
pH: 7.2
Preservative: 0.02% Sodium azide
Constituent: 99.98% PBS -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
ab113110 is purified by affinity chromatography via a peptide column. -
Clonality
Polyclonal -
Isotype
IgG
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab113110 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ICC |
Use a concentration of 10 µg/ml.
|
|
WB | (1) |
Use a concentration of 1 - 2 µg/ml. Predicted molecular weight: 157 kDa.
|
Notes |
---|
ICC
Use a concentration of 10 µg/ml. |
WB
Use a concentration of 1 - 2 µg/ml. Predicted molecular weight: 157 kDa. |
Target
-
Function
Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1. -
Tissue specificity
Expressed in breast, ductal and invasive ductal carcinomas of the breast, sporadic colorectal adenomas and carcinomas (at protein level). Expressed in fetal brain. Expressed in lung, amygdala, eye, prostate, pancreatic and prostate cancers, head and neck tumors and embryonal tumor. -
Sequence similarities
Belongs to the BCL9 family. -
Domain
Tne C-terminal domain is important for its transactivation activity. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 283149 Human
- Entrez Gene: 80288 Mouse
- Entrez Gene: 300673 Rat
- Omim: 609004 Human
- SwissProt: Q86UU0 Human
- SwissProt: Q67FY2 Mouse
- Unigene: 414740 Human
- Unigene: 370270 Mouse
-
Alternative names
- B-cell CLL antibody
- B-cell CLL/lymphoma 9-like protein antibody
- B-cell lymphoma 9-like protein antibody
see all
Images
Protocols
Datasheets and documents
-
Datasheet download
References (2)
ab113110 has been referenced in 2 publications.
- Tao B et al. Matrix stiffness promotes glioma cell stemness by activating BCL9L/Wnt/ß-catenin signaling. Aging (Albany NY) 13:5284-5296 (2021). PubMed: 33535177
- Huge N et al. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma. Hepatol Int 14:373-384 (2020). PubMed: 31440992